IJPSR (2022), Volume 13, Issue 2 (Review Article)

INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH

Received on 11 January 2021; received in revised form, 14 May 2021; accepted, 05 December 2021; published 01 February 2022

A STUDY ON THE NOSE TO BRAIN DRUG DELIVERY SYSTEM

Mrugendra B. Potdar [*1], Neetesh K. Jain [2], Sumit S. Rathod [3] and Kiran D. Patil [4]

Faculty of Pharmacy [1], Department of Pharmacology [2], Oriental University, Indore - 453555, Madhya Pradesh, India.
Department of Pharmacology [3], Department of Pharmaceutics [4], Shri Vile Parle Kelavani Mandal's, Institute of Pharmacy Dhule - 424001, Maharashtra, India.

Keywords:

Nose, Intra-Nasal, Bioavailability, Biopharmaceutical, Mucoadhesion, Drug delivery systems

Correspondence to Author:
Mr. Mrugendra B. Potdar

Research Scholar,
Faculty of Pharmacy, Department of Pharmacology, Indore - 453555, Madhya Pradesh, India.

E-mail: mrugen.potdar@gmail.com

ABSTRACT: Drugs have been controlled by the nasal route for remedial & therapeutic use since ancient times. Enthusiasm & importance for the basic impacts of drugs directed *via* the nasal route has developed to last decades. Intra-nasal drug organization provides an attractive substitute for achieving the important beneficial impacts of drugs virtually similar to the parenteral route, that may be improperly engineered on occasion or through the oral organization, that may contribute to inadequately low bioavailability of drugs. Along these lines, it is crucial to identify the potential & impediments of various nasal drug conveyance frameworks. In this way, the object of this paper is to study the different forms of pharmaceutical dosage that may be utilized in the vicinity or in a basic drug organization. It is obviously anticipated that this study would help to understand & advance expand appropriate intra-nasal strategies to meet specific restorative goals.

INTRODUCTION: The Nose to brain drug delivery system relies on the strategy in which the medication is delivered on the nasal route for system impact. The nasal drug delivery system has been perceived brilliant route of remembrance for pharmaceuticals and biopharmaceuticals. Nasal Mucosa is measured as a prospective route of the organization to accomplish a quicker and more important degree of drug retention [1]. The nasal cavity has a superior surface area, permeable endothelial film, large absolute blood flow and trembling of initial-pass digestion are these two reasons IN are Investigators focused on the nasal route for the delivery of drugs owing to their significant porousness of nasal mucosa [2].

QUICK RESPONSE CODE

DOI: 10.13040/IJPSR.0975-8232.13(2).569-78

This article can be accessed online on www.ijpsr.com

DOI link: http://dx.doi.org/10.13040/IJPSR.0975-8232.13(2).569-78

The delivery of drugs to the brain is a key test appropriate to the existence of two physiological limitations, restricting the delivery of drugs to Blood Cerebrospinal Fluid Barrier (BCSFB), Blood-Brain Barrier (BBB) and Central Nervous System (CNS). Intranasal drug delivery system is being investigated for routine and proximity drug delivery for the treatment of nearby problems such as nasal reaction, nasal infections and congestion. However, as that such decades, the Nasal path has been used by researchers as convenient, reliable, non-intrusive and secure to reach a quicker and more drastic degree of product assimilation [3].

Approaching the nose to the brain is an exciting region of importance for the straight route of medications in the nose to brain via olfactory and trigeminal nerve cells during the nose that could circumvent the BBB and reach the brain directly. The nasal mucosa olfactory locale is an immediate association between the nose and brain analyzed for CNS substitute drugs. Improvements in the bioavailability of certain drugs and remedial

proteins and peptides have been reported [4]. Drugs need to extend BBB out of circulation in the nose for brain delivery.

1. Intranasal Drug Delivery: The vast majority of accessible drugs from the AD and different CNS issues use the fringe route of the drug organization (Oral and parenteral organizations). This type of commitment decreases the adequacy and strength of the task. Treatment of drugs the major downside of the peripheral organization of the medication is the restricted supply of blood to the brain of the product fragments or complex operators [5]. It could be because of the proximity of BBB, which limits the passage of virtually all drug particles, different phytoconstituents, proteins, peptides and another huge essence; to defend the brain from some kind of mischief. At the same period, however, fermentation and enzymatic manipulation (oral organization) and structural independence (oral and parenteral) have been shown to significantly reduce drug bioavailability. Alongside that, the authoritative plasma protein, amount of transport, belated delivery to the brain by blood and fringe symptoms of system drug delivery stimulate the search for an elective pathway that legally conveys the medication to the brain. According to the situation, the intracerebro-ventricular infusion may be a preference, except the technique is profoundly invasive. It can simply be done under scandalous conditions by deeply experienced hands and appears to be practically unnecessary to use [6].

Among each complexity of brain drug delivery, the IN5 path emerges as a pleasurable and helpful methodology to facilitate sidesteps the BBB and conveys the drug directly to the brain from the nasal cavity. Specific theories and exploration indicate to iN's brain drug distribution mechanism overcome the obstacles to clinical medication transmission and guarantees the drug delivery cycle [7]. At the time, offers non-invasive and viable behavior of the CNS issue. The IN route is now the most popular route of drug organization to system circulation and topical function, yet we are concerned regarding the use of such a non-intrusive and viable route for straight brain drug delivery. William H. Frey II, 1989, found the main idea of an intranasal path for the deliverance of remedially dynamic mixtures legitimately to the CNS. From that point on, a striking report was made in the nose to brain DDS. At first, the examination focus on the iN delivery of insulin to the brain for the treatment of AD. In addition to insulin, different proteins and peptides have been shown to remain accessible for product delivery to the brain to the IN path. In the same manner, various studies lie on specific peptides and proteins (such as wheat germ agglutinin, leptin, melanocortin, oxytocin, nerve growth factor (NGF) and so on) sustain/corroborate the assumption of straight nose-to-brain drug transmission. That also a few inconsistencies in the immediate section of the drug as of the nasal cavity to the mind. A researcher's meeting did not examine such hints of estradiol in the CSF after nasal organization, whereas other researchers' gathering discovered a drug that was similar to the IN organization when contrasted with the intravenous route [8]. Comparative contradictory knowledge remains evident with IN's organization of nutrient B12 and melatonin. The discrepancy knowledge demonstrates the need for an effective nose-to-brain drug distribution check technique. Effective advancement of IN drug delivery to the brain requires an appropriate considerate of the drug transfer system, disease pathophysiology, brain life systems and various definitions as well as test boundaries [9].

2. Biopharmaceutical Consideration: The simple presence & larger surface part allow the nose potential drug delivery organ. Improving the pharmaceutical item is a vital assignment that is directly subject to its restorative destinations. Thusly lines, significant biopharmaceutical perspectives right off the bat, regardless of whether they are planned for improvement of the item, must be considered before significant worth:

- Localized delivery.
- Systemic delivery.
- Single or recurring management.

The practicality providing the possibility of meeting the restorative goals should decide if enhancing the nasal delivery system is acceptable (eller, knoester, kublik). Adherence to variables that may influence drug affidavit, maintenance & ingestion is vital to enhance the insightful structure of nasal formulations. Different physiological, anatomical & neurotic conditions should be

measured. Various forms of nasal formulations usable to United Kingdom at the point of delivery. In either event, a major factor in the preparation of nasal product delivery formulations is to get medication into an acceptable vehicle, a network which gives drug constancy & optimal distribution. Components, for example, the choice of explicit pharmaceutical excipients, delivery apparatus & processing strategies, require cautious concern. A graphical overview of each of the main boundaries of a good nasal description is exposed in **Fig. 1.**



FIG. 1: FORMULATION ELEMENTS OF NASAL PRODUCT DEVELOPMENT

3. Anatomy and Physiology of Nasal Cavity: The nose of the nasal cavity is a major organ. The nose is a complex multi-functional organ. Significant elements of the nasal cavity include air purging andolfacturing. It carries out defensive and compassionate practices. This filter warms and humidifies the ambient air by it reach the lower portions of the aviation routes. Nasal hair and in particular, nasal mucosa by its clingy body fluid cover helps prevent xenobiotics (allergens, bacteria, or distant elements) from entering the lungs. This applies to the most powerful first level of the barrier for aeronautical bodies as it adapts to more than 500 liters of air an hour in the lungs10and nasal life systems appear in **Fig. 2.**



FIG. 2: ANATOMY OF NOSE & DISTINCTIVE FUNCTIONAL REGION OF NASAL CAVITY

Mucociliary activity has expulsion of the body fluid to the nasopharynx, immunological activities include an array of healthy trained cells and absorption of endogenous substances is a further fundamental element of the nasal cavity. The nasal cavity was associated with various depressions, like the frontal, maxillary sinus, and ear was additionally filled as a thunderous body. There have been 3 specific useful areas in the nasal cavity, olfactory and respiratory vestibules and unmistakable valuable regions of the nasal cavity are exposed in **Fig. 2.**

The vestibular region is rough. 0.6 cm2 of filling an initial covered by low vascularization of the airborne portion produced differentiated squamous and keratinized epithelial cells of the nasal fur. The olfactory area is nearly the same. 15 cm^2 enables the olfactory perception to be deeply vascular zed [11]. Approximately pulmonary area 130 cm^2 presents a productive air purification system with its body fluid layer supplied by exceptionally specific cells. The thickness of this region is expanded by the separation of the cavity by horizontal dividers into 3 nasal conchae and reinforcement of the mucosa with microvilli and cilia. This region is extremely vascularzed. The back part of the nasal cavity is the nasopharynx the higher part of the nasal cavity is made up of ciliated cells and the lower part is made up of squamous epithelium. This region is the fraction of the invulnerable mucosal structure, and owing to rich vascularization, the olfactory and respiratory region can use effective assimilation surface for topically administered drugs. The olfactory area by cerebrospinal fluid (CSF) region and shortest nervous boundary to the brain are most advantageous for conceivable brain delivery in the approach of the scientist [12]. The respiratory epithelium and various parts of the nasal cavity and aeronautical route have lined with a shallow epithelium comprised essentially of two kinds of cells, globe cells (20 percent) and ciliated cells (80 percent). Different cell forms of epithelium have been associated with close intersections and the nasal epithelium group of cells is exposed in **Fig. 3.**



FIG. 3: CELL TYPES OF THE NASAL EPITHELIUM

Body fluid is persistently supplied to globet cells stuck in particulates and unavoidable flotsam and jetsam whereas propulsive power session 1,000 strokes/min) created to ciliated cells pushes the body fluid against the nasopharynx and gastrointestinal tract to the center. An effectual purifying device is mucociliary leeway. The Mucociliary leeway is roughly 20 min. because, as it can be, it is prone to exceptional variations in the entomb. Mucociliary independence relies on the ability of the cilia and the properties of the body fluid that can be compromised by severe and unceasing disease (regular temperature, unfavorably prone rhinitis) Numerous essences have an impact on the mucociliary leeway of the aeronautical routes, either by incitement or obstruction. The stimulatory effect of medications on mucociliary independence is of therapeutic importance, provided that such compounds may be conceivably used to boost the intrusive condition of mucociliary leeway. Segments (drugs and different elements) of nasally-oriented description and even expressed mucociliary freedom of failure of operation can limit their usage [13].

4. Mechanism of Drug Absorption: The biggest improvement to the removal of a drug as of the nasal cavity movement into the body membrane. superior elements effectively pass by the body's fluid layer; but, huge particles could encounter a few problems [14]. Mucous fluid includes mucin, a protein that may bind to solutes and ultimately affect the dispersion cycle. Basic changes can occur within the body fluid layer due to natural or physiological modify [15]. As a product of the medication segment into the body stream, there are

different tools for mucosal preservation. These include transcellular or basic dispersion over the layer, paracellular transport by cell development, and vesicular transcytosis. A few instruments have been suggested, but they regulate paracellular and transcellular paths [14].

Paracellular movement is mild and disconnected. There is a converse association between intranasal preservation and the atomic load in water-solvent mixtures. Helpless bioavailability was documented for drugs by an atomic weight better than 1000 Daltons. The following portion occupies transport utilizing a lipoidal route otherwise referred to as a transcellular procedure and is responsible for the lipophilic drug vehicle which shows a degree of dependence on its lipophilicity. Drugs often cross-sell films by way of a working automobile path by way of an interrupted means of transport or employing a small intersection opening [16]. Pharmaceutical absorption hindrances are likely to be metabolism before systemic processing and loss of sufficient habitat period in the nasal cavity.

5. Intra Nasal Drug Delivery Systems:

5.1.1 Nasal Drops & Sprays: Drops have among the least complicated and favorable distribution mechanisms in all formulations. The principal impediment is the lack of accuracy of the prescribed dose and the possibility of tainting through usage. Nasal drops should be treated with a pipette or squeezy tube. Such treatments are frequently suggested for the treatment of surrounding diseases, except difficulties involve microbial expansion, mucociliary breakup, and ambiguous misfortune from the nose or backside of the throat [17].

The nasal shower structure contains a chamber, a reservoir and a functioning actuator. Nasal splashes are almost other precise than drops and construct accurate dosages (25-200 µl) per shower [17]. Several investigations have exposed that nasal splashes could provide predictable portions of reproducible crest geometry. Describing in detail properties such as thixotropy, surface tension and viscosity may have an impact on bead size and portion accuracy (menaka and pandea). Various considerations, like functional force, the size of the hole and layout of the siphon, and also determine the size of the bead, can impact the nasal condition of the showers.

5.1.2 Nasal Gels: gel is a smooth, hard or semi-solid substance composed of at least two pieces that is liquid, current in a large volume. The semi-solid qualities of gels could be characterized regarding two unique mechanical properties: flexible modulus G' and viscous modulus G" [18].

The rheological assets of gels rely upon the polymer kind, fixation and corporeal condition of the gel, that range from viscous solutions (like Hypromellose, methylcellulose, thickener and chitosan) to exceptionally hard, weak gels (for instance: Gellan gum, gelatin and alginate). Bioadhesive polymers have indicated superior possible for nasal formulations and could manage rate and degree of drug discharge resultant in diminished recurrence of drug organization and enhanced patient consistence [19, 20]. In accumulation, the extended associate time management at the place of assimilation could develop drug bioavailability by slowing down mucociliary growth [21].

Gavini *et al*., pragmatic promote in the solubility of roxithromycin stack to chitosan microspheres compare and liberated drug whenever intranasal drug ingestion was estimated *in-vivo* in rodents [22]. The instrument of mucoadhesion in the nasal cavity could elucidate the variety of hypotheses, however generally recognized that the structure depends on two key stages, the contact and consolidation phases. Due to this, as formulations have bioadhesive polymers was imparted in the nasal cavity, which extends above the nasal epithelium. Because of the prolonged exterior area, the polymer chains could disperse in the corporal fluid. Which builds contact for entanglement.

Auxiliary compound bonds are then shaped amongst the polymer chains and mucin atoms [23]. Dissimilar biocompatible and biodegradable polymers havebeen utilized to form mucoadhesive systems. These integrate poly-vinyl liquor [24], chitosan [25], Carbopol 934, Sodium alginate, HPMC, Hydroxypropyl cellulose, starch and gellan gum [26]. A nasal organization using mucoadhesive gels was read for several drugs: anti-infection agents, such as roxithromycin and ciprofloxacin [27], insulin [28], scopolamine hydrochloride [29], mometasonefuroate [30], carvedilol [31], sumatriptan succinate [32], immunizations and proteins [33].

Scrutinized the plan of ciprofloxacin hydrochloride exploit HPMC and conclusion optional which bioavailability of ciprofloxacin gel definition approved with HPMC was virtually the same from the oral route [27]. Despite the majority of gels displaying shear-thinning activity (pseudo-plasticity), certain gel formulations by sufficient rheological assets cannot be simply conveyed utilizing a standard nasal splash device. In situ gelation could utilize to overcome this difficulty [34] and was studied for nasal distribution of mometasone furoate, carvedilol and flu immunization [32]. In situ gel-forming polymeric formulations were DDS which structure before the organization in the corpse, except once handled, suffer in situ gel formation. The configuration of gels depends on variables such as temperature regulation, ph shift and the occurrence of ions that medication is discharged in a persistent and prohibited approach.

5.1.3 Nasal Suspensions & Emulsions: Suspensions are utilized and tested oral medication delivery devices once in a while. Analogous to displayed watery ophthalmic deferral of soft corticosteroids, loteprednol etabonate (such as Alrex, Bausch and Lomb Pharmaceuticals), nasal watery deferral of the similar drug include microcrystalline sodium carboxymethylcellulose for modification and maintenance in the nasal cavity, was covered to Senju Pharmaceuticals Japan and designed for neigosa. Studied the nasal suspension for insulin delivery. Soya bean-inferred steryl glycoside and sterol blends (1 percent) were exploited as an assimilation enhancer and pharmacological bioavailability of 6.7 percent and 11.3 percent was obtained.

In any case, a few developers [35] indicated which emulsions were enhanced than suspensions to improve the bioavailability of inadequately dissolved medicines and the trend is comparable to nasal formulations. Improvement in retention was attributed to the solubilization of drugs and lipophilic ingestion enhancers in the organization. Additionally, other low solubility mixtures in emulsions have been planned to enhance drug solubility for example, diazepam and testosterone. Klang *et al* 2015 utilized nano-suspension to enter the brain to the nose. Detailing nanosuspension encouraged to bypass the BBB for composition among 1-500 nm. In addition, the nasal association of nano-emulsions for brain targeting has also been announced by late specialists [36].

5.1.4 Nasal Micellar & Liposomal Formulations: Various kinds of adjuvant may influence the absorption of drugs andare often required to arrive at remedial plasma levels if hydrophilic macromolecular drugs, *e.g.* peptides and proteins, were transmitted by the nasal route. Of the various surfactants exploited, bile salts were also utilized as enhancers, such as miscellaneous solutions. Tengamnuay and Mitra identified the use of sodium glycocholate micelles and micelles varied to unsaturated fat (linoleic corrosive) absorption enhancer for the dipeptide replica (D-Arg2)-cyotorphin and for insulin in rodents. The consequence of the combined micelles was synergistic and stronger measured than that of the solitary enhancer.

Blended micelles with sodium glycocholate and linoleic corrosive decreased blood glucose rates following nasal insulin organization to 47% with glucose levels after undistinguished nasal insulin dose. Unadulterated sodium glycocholate culminated in a decline to 55%. So far as the device is concerned, in the contrast between the film solubilizing effects of unadulterated bile salts, blended micelles were suggested to influence the nasal paracellular route. As a result, bile salts were known to be solubilizing agents for unsaturated fats, rendering them increasingly accessible to the nasal mucosa. Absorption altering the effect of the blended micelles was reversible following 20-40 min and morphological modifications of the nasal mucosa were only moderate to precise after 5 h of presentation.

In any case, the inference of indication catalysts in rodent nasal perfusate indicated which harmful effect of the blend micelles on the epithelial layer was significantly increased by contrasting and unadulterated sodium glycocholate and phosphate coated saline after 90 minutes of coverage [37]. In addition, liposomes have been explored as nasal drug delivery systems and increased absorption of insulin and calcitonin *in-vitro* porousness has been identified. Improvement consequence was endorsed to augmented nasal conservation of peptides. The good transporter impact for calcitonin was

established by cationic liposomes, which were established to be personally attached to the nasal mucosal surface, facilitating infiltration of the exemplified drug. Comparative surveillance was prepared for desmopressin-stacked cationic liposomes, that consequence in improved antidiuretic impacts in contrasted rodents and anionic liposomes and solutions [38] indicated augmented nasal assimilation of insulin for high film fluidity liposomes compared to increasingly rigid particles. In either scenario, absorption improving the effect of liposomes is challenging to distinguish from the enhanced impacts of specific parts, for instance, phosphatidylcholines and steryl glycosides. Proliposomes have revealed promise for nasal drug delivery. Proliposomes are smooth moving granules made of sorbitol as transporters and lipids to outline liposomal scattering in contact with water. Their benefits were a mixture of rapid onset (exterior drug) and protracted drug activity (embodied drug) as shown for propranolol and nicotine.

5.1.5 Nasal Powders: Particulate nasal dose systems are frequently structured with combining product material and excipients [39], by drying or freezing the medication [40]. Dry-powder formulation incorporating bioadhesive polymers for the nasal distribution of peptides and proteins has initially been explored. Water-insoluble cellulose subsidiaries and Carbopol 934P have blended to insulin and powder fusion was controlled nasally. The powder takes up water, spread it and puts a gel in the nasal cavity for a long period of dwelling. The decrease in glucose was 33 percent of that achieved by i.v. Infusion of a similar portion of insulin. Powder compositions for nasal drug delivery have been usually evaluated, for example for somatostatin analog with cross-linked dextran and microcrystalline cellulose, for glucagon with microcrystalline cellulose, for leuprolide and calcitonin with microcrystalline cellulose in mixture by Hydroxypropyl cellulose suzuki, y and makino, y. (1999) and for gentamicin sulfate to HPMC. Bioadhesive nasal powder comprising beclomethasone dipropionate for the healing allergic rhinitis and hydroxypropyl cellulose in the vicinity as the carrier has appreciably improved nasal habitation period contrasted and reaction organization as drops. Ugwoke *et al*. looked at apomorphine, freeze-dried lactose.

Due to such conditions, the control powder has condensed the freedom of the nasal mucociliary [41]. The dissimilarity in the nasal habitation period lies in persistent high-level plasma from the Carbopol ® concept of 52 min versus 11 min for lactose powder as maintaining comparable bioavailability. However, the most bioavailable description provided the growing storage modulus, for example, the most solid-like materials that observe the bioavailability of insulin was especially diminished following the re-organization of powder formulations [42]. While the reasons continue indistinct, it was assumed to powders weren't entirely removed from the nasal cavity after every delivery except for the corporeal barrier on the nasal mucosa that inhibited drug infiltration following administration. In this way, adhesion appears to have turned into a deterioration in bioavailability. Similarly, inorganic, water-insoluble powder formulations, *e.g.* calcium phosphates, improved drug absorption in rodents than the nasal organization, even if in vitro drug porousness did not progress across the nasal mucosa. Impediment at the company location was suggested as a probable explanation.

5.1.6 Nasal Microparticles: The usage of microparticles as further means of prolonging the period in the nasal cavity was published in 1987 [43]. Microspheres of egg whites, starch, and DEAE-dextran (diethyl aminoethyl-dextran) were recommended to assimilate water and form a gel-like layer that was gradually removed from the nasal cavity. Three hours past the organization, half of the conveyed egg whites and starch microspheres and 60% of the dextran microspheres have current at the testimonial site. Proposed that enhanced interaction time could build up substance absorption skills. As suggested, the virtual intranasal bioavailability of person growth hormone in sheep was augmented from 0.1 percent for explanation to 2.7 percent for the degradable starch microsphere program. The expansion of the absorption enhancer, lysophosphatidylcholine, advanced increased the absorption of growth hormones as a general bioavailability of 14.4 percent was accomplished. Björk (1990) indicated a decrease in plasma glucose after nasal insulin organization was similar for degradable starch microspheres (cross-linked by epichlorohydrin) and insoluble starch powder (subatomic weight 25 kDa)

except appreciably lesser for solvent starch powder (subatomic weight 11 kDa). Which argued in this way that the water absorption and water insolubility are significant limits for absorption that promote the impact of microspheres. No modification of the nasal mucosa has been identified to electron microscopy scanning after then two months of a couple of everyday organization of the starch microscope, except for minor hyperplasia in the septum divider. Even if DEAE-dextran microspheres are sturdily held in the nasal cavity, weren't effective in promoting nasal insulin absorption in rodents [44].

Insulin was extremely closely bound to the DEAE collection to be discharged through a solvent of an ionic power equivalent to physiological circumstances. Dextran microparticles without particle substitute faction induce a 25 percent to reduce in blood glucose rates concerning 40 min after the comparing and beginning stages of the company. In the previous analysis, dextran microspheres with alternative conveyances of typified insulin were considered [45]. At the stage where insulin was placed on the surface of the microsphere, a 52 percent drop in plasma glucose was observed 30 minutes after rodent organization. However, microspheres, which remembered insulin for the round frame, had reached the most extreme plasma glucose level by 30 percent after 60 min. Conceivably the partial measure of fluid in the nasal cavity is liable for pragmatic contrasts, microspheres should be swollen to discharge the whole measure of the consolidated insulin [46]. Chitosan also can be an excipient of a microparticle drug delivery system. In vivo experiments in sheep revealed half-existence of nasal leeway for chitosan microparticles of 115 min in comparison and 43 min in the polymer solution. In common, chitosan formulations, whether as microparticle and powders, appear higher inclusion impact than chitosan solutions [47]. In addition, late solid lipid nanoparticles have already demonstrated positive results [48, 49] and seem to be extending the brain treatment of rosmarinic corrosive after nasal injection for the possible control of Huntington's disease [49].

6. Limitations of Nasal Drug Delivery System: Nose to brain organization is a narrative technique of every pharmaceutical composition that guides the transfer of a medicinal composition during the nose to the brain utilizing olfactory or trigeminal nerve route bypass BBB. The brain drug delivery structure is suitable for the diagnosis of a variety of CNS diseases as brain tumors, Parkinson's disease and further neurodegenerative conditions. It is important to move huge atomic weight mixtures like proteins and peptides. In this medication distribution, the medicinal molecule has a legal effect on bloodstream circulation and can inhibit Presystolic digestion.

It is non-intrusive and effective nose to brain organization is a narrative Fast end of nasal drug material attributable to mucociliary clearance. The nasal cavity gives a slightly lower surface absorption as a comparison to the gastrointestinal zone [50, 51]. Absorption enhancers could cause mucosal poisoning utilized in the plan [52]. Less bioavailability can consequence of enzymatic degradation and digestion of the mucosal surface. Mechanical failure of the dosing system may arise due to an ill-advised organizational strategy [53, 54].

CONCLUSION: Over a decade ago, the nasal cavity became one of the promising and conceivably adaptable routes for drug delivery. Its innovative capacity to improve drug discharge by carrying through the hepatic initial-pass absorption and subsequent transmission of drugs to the brain is strongly assured in the region of drug distribution. A rising group of proof related to nasal drug delivery proposed that can be utilized for challenge drugs that may encourage challenges in the pharmaceutical production and delivery of drugs. A variety of pharmaceutical dosage structures and the ability to be used by nearby or systemic drug organizations have been discussed in their audit study. It is instinctively probable that such an audit will help to appreciate and auxiliary expands intranasal formulations to get explicit restorative destinations. Be that as it may, the various specialized and ground-based issues, which are further highlighted in this audit article, remain an obstacle to be overcome together for the maximum capacity to be determined.

ACKNOWLEDGMENT: The authors acknowledge the Management and Principal of Oriental University, Indore and SVKMs Institute of

Pharmacy, Dhule, for providing the platform for this review.

CONFLICTS OF INTEREST: The author reports no conflicts of interest in this work.

REFERENCES:

1. Mittal D, Ali A, Shadab MD, Baboota S, Sahni JK and Ali J: Insights into direct nose to brain delivery: current status and future perspective. Drug Deli Early Online 2013; 1-12.
2. Ugwoke MI, Agu RU, Verbeke N and Kinget R: Nasal mucoadhesive drug delivery: Background, applications, trends and future perspectives. Advanced Drug Delivery Reviews 2005; 57: 1640-1665.
3. Garcia GE, Andrieux K, Gilb S and Couvreur P: Colloidal carriers and blood–brain barrier (BBB) translocation: A way to deliver drugs to the brain. International Journal of Pharmaceutics 2005; 298: 274-92.
4. Kumar M, Mishra A, Babbar AK, Mishra AK, Mishra P and Pathak K: Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. International Journal of Pharmaceutics 2008; 358: 285-91.
5. Lochhead JJ, Wolak DJ, Pizzo ME and Thorne RG: Rapid transport within cerebral perivascular spaces underlies widespread tracer distribution in the brain after intranasal administration. J CerebBlo Flow Meta 2015; 35: 371-81.
6. Jiang Y, Zhu J, Xu G and Liu X: Intranasal delivery of stem cells to the brain. EODD 2011; 8; 623-32.
7. Lochhead JJ and Thorne RG: Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev 2012; 64; 614-28.
8. Al-Ghananeem AM, Traboulsi AA, Dittert LW and Hussain AA: Targeted brain delivery of 17 beta-estradiolvia nasally administered water soluble prodrugs. AAPS Pharm Sci Tech 2002; 5(3).
9. Dhuria SV, Hanson LR and Frey II WH: Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci 2010; 99; 1654-73.
10. Illum L and Farraj NF: Investigation of the nasal absorption of biosynthetic human growth hormone in sheep-use of a bioadhesive microsphere delivery system. International J of Pharmaceutics 1990; 63(3): 207-11.
11. Misra A; Kher G: Drug Delivery Systems from Nose to Brain. Current Pharmaceutical Biotechnology 2012; 13: 2355-79.
12. Bahadur S and Pathak K: Physicochemical and physiological considerations for efficient Nose-to-brain targeting. Expert Opinion on Drug Delivery 2012; 9(1): 19-31.
13. Basu S and Bandopadhyay AK: Nasal Drug Delivery: An Overview. International Journal Pharmaceutical Science Technology 2010; 1: 1-20.
14. Huang CH, Kimura R, Nassar RB and Hussain A: Mechanism of nasal absorption of drugs I: Physicochemical parameters influencing the rate of in situ nasal absorption of drugs in rats. Journal of Pharmaceutical Sciences 1985; 74(6): 608-11.
15. Shinichiro H, Takatsuka Y and Hiroyuki M: Mechanisms for the enhancement of the nasal absorption of insulin by surfactants. International Journal of Pharmaceutics 1981; 9(2): 173-84.
16. Duvvuri S, Majumdar S and Mitra AK: Drug delivery to the retina: challenges and opportunities. Expert Opinion on Biological Therapy 2003; 3(1): 45-56.
17. Hasçiçek C, Gönül N and Erk N: Mucoadhesive microspheres containing gentamicin sulfate for nasal administration: preparation and in-vitro characterization. IlFarmaco 2003; 58(1): 11-16.
18. Chaturvedi M, Kumar M and Pathak K: A review on mucoadhesive polymer used innasal drug delivery system. Journal of Advanced Pharmaceutical Technology and Research 2011; 2(4):215..
19. Rathbone MJ, Hadgraft J and Roberts MS: Modified-release drug delivery technology. Eds CRC Press 2002; 126, 741.
20. Nakamura K, Tanaka Y and Sakurai M: Dynamic mechanical properties of aqueous gellan solutions in the sol–gel transition region Carbohydrate Polymers 1996; 30: 10-08.
21. Patil SB and Sawant KK: Mucoadhesive microspheres: a promising tool in drug delivery. Current drug delivery 2008; 5(4): 312-18.
22. Gavini E, Rassu G, Ferraro L, Generosi A, Rau JV, Brunetti A and Dalpiaz A: Influence of chitosan glutamate on the in-vivo intranasal absorption of rokitamycin from microspheres. J of Pharma Scienc 2011; 100(4): 1488-02.
23. Gavini E, Rassu G, Ferraro L, Generosi A, Rau JV, Brunetti A and Dalpiaz A: Influence of chitosan glutamate on the in-vivo intranasal absorption of rokitamycin from microspheres. J of Pharmaceut Sci 2011; 100(4): 1488-02.
24. Mahdi MH, Conway BR and Smith AM: Development of mucoadhesivesprayablegellan gum fluid gels. International Journal of Pharmaceutics 2015; 488(1): 12-19.
25. Swamy NGN and Abbas Z: Preparation and in vitro characterization of mucoadhesive polyvinyl alcohol microspheres containing amlodipine besylate for nasal administration. Indian Journal of Pharmaceutical Education and Research 2012; 46(1): 55.
26. Casettari L and Illum L: Chitosan in nasal delivery systems for therapeutic drugs. Journal of Controlled Release 2014; 190: 189-200.
27. Rathananand M, Kumar DS, Shirwaikar A, Kumar R, Sampath Kumar D and Prasad RS: Preparation of mucoadhesive microspheres for nasal delivery by spray drying. Indian J of Pharmaceutical Scien 2007; 69(5): 651.
28. Ugwoke MI, Agu RU, Verbeke N and Kinget R: Nasal mucoadhesive drug delivery: Background, applications, trends and future perspectives. Advanced Drug Delivery Reviews 2005; 57: 1640-65.
29. Dyer AM, Watts P and Castile J: Nasal delivery of insulin using novel chitosan based formulations: a comparative study in two animal models between simple chitosan formulations and chitosan nanoparticles. Pharmaceutical Research 2002; 19(7):998-1008.
30. Cao SL, Zhang QZ and Jiang XG: Preparation of ion-activated in situ gel systems of scopolamine hydrobromide and evaluation of its antimotion sickness efficacy. Acta Pharmacological Sinica 2007; 28(4): 584-90.
31. Zitt M, Kosoglou T and Hubbell J: Mometasonefuroate nasal spray. Drug Safety 2007; 30.
32. Nilesh S: Nanosuspension based in situ gelling nasal spray of carvedilol: development, in-vitro and in-vivo characterization. AAPS Pharm Sci Tech 2013; 14(1): 189-99.
33. Galgatte UC, Kumbhar AB and Chaudhari PD: Development of *in-situ* gel for nasal delivery: design, optimization, *in-vitro* and *in-vivo* evaluation. Drug Delivery 2014; 21(1): 62-73.
34. Vila A, Sanchez A, Tobi M, Calvo P and Alonso MJ: Design of biodegradable particles for protein delivery. Journal of Controlled Release 2002; 78(1): 15-24.

35. Madan M, Lewis MB, Udupa S and Baig N: In situ forming polymeric drug delivery systems. Indian Journal Pharmaceutical Sciences 2009; 71: 242-51.
36. Aikawa K, Matsumoto Uda K: Prolonged release of drug from o/w emulsion and residence in rat nasal cavity. Pharmaceutical Development & Technology 1998; 3(4): 461-69.
37. Shinde RL, Bharkad GP and Devarajan PV: Intranasal microemulsion for targeted nose to brain delivery in neurocysticercosis: role of docosahexaenoic acid. European J of Pharmaceuti and Biopha 2015; 96: 363-79.
38. Shao Z and Mitra AK: Bile salt–fatty acid mixed micelles as nasal absorption promoters. III. Effects on nasal transport and enzymatic degradation of acyclovir prodrugs. Pharmaceutical Research 1994; 11(2): 243-50.
39. Law SL and Shih CL: Characterization of calcitonin-containing liposome formulations for intranasal delivery. Journal of Microencapsulation 2001; 18(2): 211-21.
40. Ishikawa, E., Yanaka, K: Reversible dementia in patients with chronic subdural hematomas. Journal of Neurosurgery, 2002; 96(4), 680-683.
41. Jadhav KR, Gambhire MN, Shaikh IM, Kadam VJ and Pisal SS: Nasal Drug Delivery System-Factors Affecting and Applications. Current Drug Thera 2007; 2(1): 27-38.
42. Ugwoke MI, Agu RU, Verbeke N and Kinget R: Nasal mucoadhesive drug delivery: Background, applications, trends and future perspectives. Advanced Drug Delivery Reviews 2005; 57: 1640-65.
43. Callens C and Remon JP: Evaluation of starch–maltodextrin-Carbopol® 974 P mixtures for the nasal delivery of insulin in rabbits. Journal of Controlled Release 2000; 66(2): 215-20.
44. Illum L: Nasal drug delivery-possibilities, problems and solutions. Journal of Controlled Release 2003; 87: 187-98.
45. Edman P, Björk E and Ryden L: (Microspheres as a nasal delivery system for peptide drugs. Journal of Controlled Release 1992; 21(1): 165-72.
46. Pereswetoff-Morath L: Microspheres as nasal drug delivery systems. Advanced Drug Delivery Reviews 1998; 29(1): 185-94.
47. Pereswetoff-Morath L and Edman P: Dextran microspheres as a potential nasal drug delivery system for in-sulin in-vitro and in-vivo properties. International Journal of Pharmaceutics 1995; 124(1): 37-44.
48. Krauland AH, Guggi D and Bernkop-Schnürch A: Thiolated chitosan microparticles: a vehicle for nasal peptide drug delivery. Inter J of Pharmaceutics 2006.
49. Scalia S, Young PM and Traini D: Solid lipid microparticles as an approach to drug delivery. Expert Opinion on Drug Delivery 2015; 12(4).
50. Otto DP, Otto A and De Villiers MM: Differences in physicochemical properties to consider in the design, evaluation and choicebetweenmicroparticles and nanoparticles for drug delivery. Expert Opinion in Drug Delivery 2015; 12(5): 763-777.
51. Bhatt R, Singh D, Prakash A and Mishra N: Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington's disease. Drug Delivery 2015; 22(7): 931-39.
52. Rahisuddin and Hussain AA: Intranasal drug delivery. Advanced Drug Delivery Reviews 1998; 29: 39-49.
53. Kamble MS, Bhalerao KK, Bhosale AV and Chaudhari PD: A Review on Nose-To-Brain Drug Delivery. Internat J of Pharmac and Chemical Sci 2013; 2(1): 516-25.
54. Putheti RR, Patil MC and Obire O: Nasal Drug delivery in Pharmaceutical and biotechnology: present and future. E-Journal of Science & Technology E-JST 2009: (3): 1-21.

How to cite this article:
Potdar MB, Jain NK, Rathod SS and Patil KD: A study on the nose to brain drug delivery system. Int J Pharm Sci & Res 2022; 13(2): 569-78. doi: 10.13040/IJPSR.0975-8232.13(2).569-78.